Welcome to our dedicated page for ABGI news (Ticker: ABGI), a resource for investors and traders seeking the latest updates and insights on ABGI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ABGI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ABGI's position in the market.
ABG Acquisition Corp. I (Nasdaq: ABGI) announces the redemption of its publicly held Class A ordinary shares, effective February 28, 2023. The expected redemption price is approximately $10.188 per share, net of taxes and dissolution expenses. Shareholders need to provide their shares to the Company's transfer agent, Continental Stock Transfer & Trust Company, to receive the Redemption Amount. Following February 19, 2023, the Company has ceased operations except for winding up its business. Additionally, ABGI plans to file a Form 25 with the U.S. Securities and Exchange Commission to delist its securities and subsequently file a Form 15 to terminate registration under the Exchange Act.
ABG Acquisition Corp. I (Nasdaq: ABGI) announced that its publicly held Class A ordinary shares will be deemed cancelled as of February 21, 2023, due to the inability to complete an initial business combination within the stipulated timeframe. Shareholders will receive a per-share redemption price from the Trust Account. Following this, the company will cease operations except for winding up its affairs. The shares will cease trading on Nasdaq on February 17, 2023, and the company plans to delist its securities and terminate their registration with the SEC. The management has waived redemption rights for certain shares in private placement.
FAQ
What is the market cap of ABGI (ABGI)?
